{
    "root": "b18bab5f-8b2c-4685-8c0e-aa6486d67a08",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Glimepiride"
    },
    "value": "20250401",
    "ingredients": [
        {
            "name": "GLIMEPIRIDE",
            "code": "6KY687524K"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "PEG-20 SORBITAN OLEATE",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        }
    ],
    "indications": "Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1)].\n                     Limitations of Use\n                      Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "contraindications": "Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1-2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. ( 2.1 ) Administer with breakfast or first meal of the day. ( 2.1 ) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). ( 2.1 )",
    "warningsAndPrecautions": "Product:    50090-7187\n                  NDC:    50090-7187-0   30 TABLET in a BOTTLE\n                  NDC:    50090-7187-1   100 TABLET in a BOTTLE\n                  NDC:    50090-7187-2   90 TABLET in a BOTTLE",
    "adverseReactions": "Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to:\n                  \n                      Glimepiride or any of the product's ingredients [see Warnings and Precautions (5.2)].\n                     Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives."
}